T. Schluep

发表

Cyclodextrin-modified polyethylenimine polymers for gene delivery.

Mark E. Davis, Suzie H Pun, S. Pun, 2004, Bioconjugate chemistry.

Immobilization of oligonucleotides on a large pore support for plasmid purification by triplex affinity interaction

C. Cooney, T. Schluep, 1999, Bioseparation.

Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models

Mark E. Davis, Y. Yen, Jianyi Wang, 2009, Clinical Cancer Research.

JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

M. Biermer, N. Goeyvaerts, W. Talloen, 2022, Antiviral therapy.

Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.

C. Trautwein, T. Schluep, R. Loomba, 2022, The New England journal of medicine.

α-Methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy

T. Schluep, K. Rodgers, Jungyeon Hwang, 2008, International journal of nanomedicine.

Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses.

H. Engler, B. Hutchins, S. Sutjipto, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.

M. Biermer, M. Yuen, D. Wong, 2022, Journal of hepatology.

First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors

Mark E. Davis, Y. Yen, T. Schluep, 2007 .

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models

Jianjun Cheng, Mark E. Davis, Derek W Bartlett, 2006, Clinical Cancer Research.

Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice

Jianjun Cheng, Mark E. Davis, Jianjun Cheng, 2006, Cancer Chemotherapy and Pharmacology.

Synthetic biocompatible cyclodextrin-based constructs for local gene delivery to improve cutaneous wound healing.

Mark E. Davis, S. Pun, N. Bellocq, 2004, Bioconjugate chemistry.

Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.

M. Yuen, Ching-lung Lai, D. Lewis, 2015, Antiviral research.

Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials

J. Heidel, T. Schluep, 2012, Journal of drug delivery.

Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.

D. Lewis, R. Gish, T. Schluep, 2015, Antiviral research.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg

S. Kanner, M. Yuen, D. Lewis, 2017, Science Translational Medicine.

PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold

M. Yuen, D. Wong, R. Gish, 2019, Journal of Hepatology.

Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas.

B. Badie, T. Schluep, D. Alizadeh, 2010, Nanomedicine : nanotechnology, biology, and medicine.

Characterization of empty capsids from a conditionally replicating adenovirus for gene therapy.

B. Hutchins, S. Sutjipto, Mark Horn, 2005, Human gene therapy.

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Mark E. Davis, J. Zuckerman, Y. Yen, 2013, Proceedings of the National Academy of Sciences.

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Yun Yen, Glen J. Weiss, Mark E. Davis, 2013, Investigational New Drugs.

CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development

S. Eliasof, T. Schluep, Jungyeon Hwang, 2011, Current bioactive compounds.

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements

Mark E. Davis, Johannes Czernin, C. H. J. Choi, 2009, Proceedings of the National Academy of Sciences.

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection

M. Manns, M. Yuen, R. Gish, 2020, Hepatology.

Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography.

C. Cooney, D. Prazeres, T. Schluep, 1998, Journal of chromatography. A.

Initial transient effects during cross flow microfiltration of yeast suspensions

T. Schluep, F. Widmer, 1996 .

Polymeric Tubulysin-Peptide Nanoparticles with Potent Antitumor Activity

G. Jensen, T. Schluep, Thomas Schluep, 2009, Clinical Cancer Research.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population

R. Gish, J. Lau, T. Schluep, 2017 .

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

M. Yuen, R. Gish, J. Lau, 2017 .

Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

M. Yuen, R. Gish, R. Hammond, 2016 .

Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers

D. Lewis, R. Gish, T. Schluep, 2016, Clinical pharmacology in drug development.

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

M. Yuen, D. Wong, R. Gish, 2021, Gut.

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

M. Yuen, R. Gish, J. Lau, 2018 .

Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment

M. Biermer, Wei Cheng, R. Gish, 2020, Journal of Hepatology.

Purification of plasmids by triplex affinity interaction.

C L Cooney, C. Cooney, T. Schluep, 1998, Nucleic acids research.

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001).

J. Brugarolas, E. Lam, B. Rini, 2022, Journal of Clinical Oncology.

A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors

Mark E. Davis, Y. Yen, T. Schluep, 2008 .

Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520

M. Yuen, R. Gish, J. Lau, 2016 .

Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis

T. Schluep, P. Kuehl, Xiaokai Li, 2018, Cystic fibrosis.

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

J. Brugarolas, T. Schluep, N. Tannir, 2024, Clinical cancer research : an official journal of the American Association for Cancer Research.